Other mutations such as TP53, SMAD4, and CDKN2A have been described in pancreatic adenocarcinoma and carcinoma derived from IPMN, however, their dosage in cystic fluid and their use in clinical practice have not been widely evaluated yet [79]. Here, TP53 is linked to pancreatic adenocarcinoma.